Table 1: Laboratory results in RA and control healthy group (M ± SD)

Non-treated RA
Group NO 35
( M ± SD )
RAsero-
NO 18
( M ± SD )
RAsero+
NO 17
( M ± SD )
Control healthy group
NO 35
( M ± SD )
Positive/ negative Positive/ negative Positive/ negative Positive/ negative
ADMA
+ > 0.75
(micromol/L )
13/22
1,096 (± 0,68)
(0,25-3,1)
9/9
1,12 (± 0,58)
(0,32-2,1)
4/13
1,07 (± 0,79)
(0,25-3,1)
8/27
1,00 (± 0,50)
(0,26-1,91)
RF
+ 30 ≥ IU/ml
17/18
346,15 (± 625,22 )
(0,00-1920)
0/18
0,00 (± 0,00 )
(0,00-0,00)
17/0
712,67 (± 743,72 )
(30-1920)
2/33
13,71 (± 38,73 )
(0,00-120)
CRP
+ 12 ≥ mg/L
14/21
46,86 (± 79,19 )
(0,00-384)
3/15
8,66 (± 24,62 )
(0,00-96)
13/4
87,31 (± 96,44 )
(0,00-384)
4/31
5,48 (± 12,80 )
(0,00-48)
ESR + ≥ 16 27/8
48,62 (± 39,81 )
(2,0-120)
13/5
43,94 (± 39,82 )
(2,0-120)
14/3
53,58 (± 40,39 )
(5,0-120)
4/31
9,42 (± 8,21 )
(2,0-44)
ACPA antibodies
+ ≥ 1,26
23/12
1,71 (± 0,69 )
(0,92-3,0)
11/7
1,56 (± 0,59 )
(0,93-2,6)
12/5
1,87 (± 0,77 )
(0,92-3,0)
1/34
0,95 (± 0,10 )
(0,90-1,38)
DAS 28
+ ≥ 3,2
28/7
4,79 (± 1,56 )
(1,85-7,03)
13/5
4,56 (± 1,76 )
(1,85-7,03)
15/2
5,04 (± 1,33 )
(2,47-6,83)
0/35
0,00 (± 0,00 )
(0,00-0,00)
Morning stiffness
+ > 0 min
26/9
43,20 (± 65,13 )
( 0-300 )
14/4
57,50 (± 81,40 )
(0-300)
12/5
28,05 (± 38,72 )
(0-120)
0/35
0,00 (± 0,00 )
(0,00-0,00)